Piramal Receives GLP Compliance Certification for Indian FacilityBy
Piramal Enterprises Limited (PEL) reports that its Good Laboratory Practices (GLP) Department at Research & Development (R&D) facility in Goregaon, Mumbai has received the GLP Compliance Certification from the National Good Laboratory Practice Compliance Monitoring Authority (NGCMA), Government of India.
GLP is a quality system concerned with the organizational process and conditions under which non-clinical health and environmental safety studies are performed. The R&D facility in Goregaon, Mumbai is engaged in drug discovery and development of new chemical entities (NCE) in the area of oncology and metabolic disorders.
The 3,450-square foot GLP facility is a part of 200,000-square foot. fully integrated NCE R&D unit which houses more than 400 scientists. Since its inauguration in June 2012, PEL has made investments in this in-house facility. The GLP certification will enable PEL to do most of the investigational new drug (IND) support studies in-house to enable shortening the turnaround time for its R&D projects and help it become more cost efficient. Earlier, PEL used to conduct GLP studies externally. However, now with this in-house facility, it will enable faster access to bio-analytical and toxicology data and better control on project timelines.
The NCE Research division of PEL focuses on the discovery and development of innovative small molecule medicines in the therapy areas of oncology and metabolic disorders.